In the mid-20th century, Hans Ussing developed a chamber that allowed for the simultaneous measurement of current and labeled probe flux across epithelia. Using frog skin as a model, Ussing used his results to propose mechanisms of transcellular Na ϩ and K ϩ transport across apical (exterior/luminal) and basolateral (interior) membranes that is essentially unchanged today. Others took advantage of Ussing's chambers to study mucosal tissues, including bladder and intestines. It quickly became clear that, in some tissues, passive paracellular flux, i.e., across the tight junction, was an important component of overall transepithelial transport. Subsequent work demonstrated that activation of the apical Na ϩ -glucose cotransporter SGLT1 regulated paracellular permeability such that intestinal paracellular transport could coordinate with and amplify transcellular transport. Intermediates in this process include activation of p38 MAPK, the apical Na ϩ /H ϩ exchanger NHE3, and myosin light chain kinase (MLCK). Investigators then focused on these processes in disease. They found that TNF induces barrier dysfunction via MLCK activation and downstream caveolin-1-dependent endocytosis of the tight junction protein occludin. TNF also inhibited NHE3, and both barrier loss and PKC␣-dependent NHE3 inhibition were required for TNF-induced acute diarrhea, emphasizing the interplay between transcellular and paracellular transport. Finally, studies using immunemediated inflammatory bowel disease models showed that mice lacking epithelial MLCK were initially protected, but became ill as epithelial damage progressed and provided a tight junction-independent means of barrier loss. None of these advances would have been possible without the insights provided by Ussing and others using Ussing's ingenious, and still useful, chambers.
FOR THE PAST CENTURY, investigators have studied ion flux across membranes. In the first half of the 20th century, it was shown that cells handle Na ϩ and K ϩ ions differently, and that Na ϩ was actively extruded by many cells. Measurement of ion transport across epithelial barriers was, however, a more challenging problem (51) . In 1951, Hans Ussing made a giant leap in overcoming this challenge (95) . He developed an apparatus with paired compartments between which a tissue, e.g., frog skin, was mounted (96) (Fig. 1A) . By putting the same solution on both sides and short-circuiting the transepithelial electrical potential, Ussing was able to simultaneously measure current and 24 Na ϩ flux across frog skin. This allowed him to calculate the electrical resistance to Na ϩ diffusion and the electromotive force of the active Na ϩ transport system. Through a series of manipulations to alter potential difference across the skin without affecting Na transport in non-short-circuited skin, Ussing found that Na flux and current were closely correlated under all conditions. Ussing also applied defined chemical or electrical potentials across the skin to determine, in relative terms, the electromotive force of active Na transport (96) . While important, the results were not entirely unexpected, as others (28, 82) had measured current across short-circuited frog skin and Ussing himself had previously assessed 24 Na ϩ flux across frog skin (51) . The advance here was developing a device that allowed simultaneous measurement of transport using electrical and chemical methods. This allowed Ussing to show that active Na ϩ transport was entirely responsible for the measured current (96) . He was also able to conclude that "the active sodium transport mechanism is located at the inner border (i.e., the interior tissue interface) and should possibly be considered a forced exchange of Na ϩ with K ϩ from the inner solution" (48) (Fig. 1B ). This was followed by studies using the Ussing chamber to show that active transport of Na ϩ and K ϩ are linked (10) and that, under most conditions, Cl Ϫ transport across frog skin is passive (43, 49) . Thus, by combining electrical and chemical measurements and applying a great deal of precision and creativity, Ussing and others were able to rapidly advance our understanding of both active and passive transport across epithelia. It did not take long before other investigators began using the chambers and methods of analyses developed by Ussing to study other transporting epithelia, including those within the gastrointestinal tract (6, 29, 70) . Space prohibits a complete discussion of the important discoveries made during this time. Because there has been so much important work done in these areas, the discussion is necessarily incomplete, and many paradigm-shifting and other significant studies are not presented. A number of outstanding reviews on the topic have, however, been published (5, 8, 20, 31, 41, 42, 44, 46, 50, 71, 76, 98 -101) .
While Ussing discovered processes of ion transport, others concentrated on the structures relevant to transport and barrier functions. With the development of the electron microscope and a variety of ways to prepare tissues for analysis came an explosion of morphologic analyses of never-before-seen structures. Farquhar and Palade (21) described intercellular junctions of simple epithelia and found shared features across diverse tissues. They took advantage of experimental hemoglobinuria and the electron-dense nature of iron to show that hemoglobin within the nephron lumen was unable to cross the zonula occludens (ZO), or tight junction (21) . This and the detailed morphological studies that followed (32, 81) supported the conclusion that "the tight junction is impervious to concentrated protein solutions and appears to function as a diffusion barrier or 'seal'" (21) . It did not take long, however, for Machen and others (53) to combine ultrastructural analyses with transport physiology. These studies rapidly led to the inescapable conclusion that "salt-transporting epithelia [should be divided] into two main groups, those with "leaky" junctional complexes and those with tight junctional complexesѧ" (53) . Examples of the latter include frog skin and toad urinary bladder, while gallbladder and ileum are examples of leaky epithelia.
Despite recognizing two classes of tight junctions, the physiological importance of "leaky" tight junctions had yet to be defined. Nevertheless, a logarithmic relationship between the number of strands seen in freeze-fracture replicas and measured electrical resistance was demonstrated in diverse epithelia (14, 15) . Such a relationship could be explained by pores within the strands. While he did not suspect that pores would be found within tight junctions, and the topic of tight junctions remains controversial (47), Ussing did theorize, in 1957, that water transport across the skin was passive and occurred via pores (2) . He also showed that osmotically driven water movement could result in flux of solutes across the same pores via solvent drag (2) . Three decades later, Pappenheimer, Madara, and Reiss demonstrated the presence of regulated solvent drag, triggered by Na ϩ -nutrient cotransport and accompanied by increased tight junction permeability to small molecules, in rodent small intestine (59, 66, 67) . These data also provide a structural basis for Meddings' observation that, despite saturation of specific D-glucose update at 50 -60 mM, uptake of L-glucose, which is not recognized by the Na ϩ -glucose cotransporter, continued to increase at concentrations exceeding 100 mM in rat jejunum (64) ( Fig. 2A) . In other words, these Fig. 1 . A: Ussing's original chamber. By short-circuiting the transepithelial electrical potential, Ussing could simultaneously measure Na 24 flux and current across a given sample tissue (96) . This allowed him to accurately assess active transport across epithelia. I, microammeter; V, voltmeter; A, apical side of tissue; B, basolateral side of tissue. B: Koefoed-Johnsen and Ussing (48) proposed passive Na ϩ across the outer membrane and active exchange of Na ϩ for K ϩ at the inner membrane. Comparison of interactions between active and passive transport in two different epithelia. A: in gastrointestinal (GI) epithelium, SGLT1-mediated Na ϩ -glucose cotransport activates Na ϩ /H ϩ exchanger (NHE3)-mediated Na ϩ absorption and also increases paracellular permeability to small molecules. Together with the osmotic gradient generated by transcellular transport, the increased paracellular permeability allows enhanced passive glucose uptake, as measured by L-glucose (which is not transported by SGLT1) by solvent drag, thereby increasing overall nutrient absorption. B: at high luminal glucose concentrations, paracellular flux via solvent drag can represent a significant fraction of total glucose absorption. C and D: Na ϩ -glucose cotransport in renal tubular epithelium does regulate tight junction permeability. Solvent drag does not significantly amplify transcellular glucose absorption, resulting in excess glucose in the urine at high blood glucose concentrations.
data indicate the existence of a passive transport process that lacks stereospecific recognition of D-glucose. This passive process is explained by solvent drag as a result of osmotically driven water absorption and resulting paracellular absorption, e.g., of L-glucose, across tight junctions with enhanced permeability to small molecules. While the best available data suggest that solvent drag is an important mechanism of intestinal nutrient absorption, support for this is not universal. With rare exception, however, careful review of studies that failed to detect solvent drag-mediated absorption of water and nutrients shows that there was little transport of any sort measured (19, 24 -27, 30, 57, 80, 90, 92-94) .
Solvent drag allows the intestine to absorb all luminal glucose, even when concentrations exceed the capacity of the transcellular transport system; at low concentrations, the transcellular pathway absorbs luminal glucose, but as concentrations increase, a growing fraction of glucose absorption occurs via the paracellular pathway ( Fig. 2B ). Similar processes likely contribute to amino acid absorption (3, 58) . It should be noted that an alternative explanation for passive transepithelial glucose absorption has been suggested based on the observation that the facilitated glucose transporter GLUT2 is recruited to the brush border membrane following Na ϩ -glucose cotransporter SGLT1 activation (45) . While this could establish a passive, transcellular route for D-glucose absorption, it fails to account for the increased transepithelial flux of mannitol and L-glucose following SGLT1 activation and, therefore cannot explain the increased paracellular absorption observed during active Na ϩ -glucose cotransport. Solvent drag in the intestine contrasts sharply with the situation in the kidney, where excessively high levels of blood glucose are partially corrected by urinary excretion due to the inability of the nephron to reabsorb glucose that exceeds the capacity of the transcellular pathway ( Fig. 2, C and D) . The evolutionary advantage of intestinal solvent drag at times when meals were irregularly spaced may therefore have been enormous.
This new understanding of tight junction permeability as a dynamic, rather than static, entity and the profound impact of paracellular flux on overall transepithelial transport led to interest in the mechanisms responsible for these regulatory processes. As a reductionist model, the well-differentiated Caco-2 BBe intestinal epithelial cell line was transfected to express the intestinal Na ϩglucose cotransporter, SGLT1 (89) . Activation of apical Na ϩglucose cotransport triggered a reversible increase in paracellular conductance of ions and small, glucose-sized molecules, e.g., mannitol, but not the larger paracellular probe inulin (91) . Like glucose-elicited tight junction regulation in rodent mucosae (3), the SGLT1 inhibitor phlorizin prevented paracellular permeability increases in SGLT1-expressing Caco-2 BBe monolayers (91). This validated the Caco-2 BBe model as a tool with which to define the molecular mechanisms underlying physiological tight junction regulation.
Morphological studies in rodent mucosae had identified two principal changes induced by activation of Na ϩ -glucose cotransport; development of intrajunctional dilatations and perijunctional cytoskeletal condensation (3) . The latter suggested that cytoskeletal, i.e., actomyosin, contraction, and evidence of this occurring in SGLT1-expressing Caco-2 BBe monolayers was therefore sought. Indeed, Na ϩ -glucose cotransport resulted in a greater than twofold increase in phosphorylation of the myosin regulatory light chain (MLC), a biochemical marker of actomyosin contraction (91) . Both MLC phosphorylation and increased tight junction permeability after activation of Na ϩ -glucose cotransport could be blocked by the relatively nonspecific myosin light chain kinase (MLCK) inhibitors ML-7 and ML-9 (91) as well as the highly specific peptide inhibitor of MLCK, PIK (105) . ML-9 also blocked paracellular permeability increases in rodent small intestine (91) but did not prevent development of intrajunctional dilatations (Turner JR and Madara JL, unpublished observations). The latter observation suggests that the dilatations formed as a consequence of the massive water absorption that occurs in response to transcellular Na ϩ and glucose absorption and were not a specific morphological feature of tight junction regulation. Finally, analysis of human jejunal mucosae showed that Na ϩ -glucose cotransport increased paracellular permeability and that this was associated with enhanced MLC phosphorylation within the perijunctional actomyosin ring (7) . Overall, these studies marked the start of an integrated understanding of the structural and functional mechanisms of tight junction remodeling.
Coordinated Regulation of Transcellular and Paracellular Transport
After MLCK was identified as a critical intermediate in Na ϩ -glucose cotransport-induced tight junction regulation, efforts focused on elucidating the events that preceded and followed MLCK activation. One potential link could be the cellular volume increase, and subsequent regulated volume decrease, that follow initiation of Na ϩ -glucose cotransport. One study showed that extracellular Na ϩ in general, and basolateral Na ϩ /H ϩ exchange mediated by NHE1 in particular, was necessary for the regulated volume decrease activated by treatment of rodent jejunal villus epithelia with 5% hypotonic media, which induced cell swelling of a magnitude similar to Na ϩ -glucose cotransport (54, 55) . Subsequent analysis of Na ϩ /H ϩ exchange in SGLT1-expressing Caco-2 BBe monolayers failed to demonstrate NHE1 regulation, but instead showed that the apical Na ϩ /H ϩ exchanger NHE3 was activated following initiation of Na ϩglucose cotransport (87) . This difference is not particularly surprising since, despite similar volume changes, signaling events differ in regulated volume decreases following hypotonic or Na ϩ -nutrient cotransport-induced cell swelling (56) .
Increased NHE3-mediated transport was due to rapid trafficking of the transporter from subapical cytoplasmic vesicles to the brush border (104) . This was triggered by a signaling cascade in which Na ϩ -glucose cotransport resulted in phosphorylation and activation of p38 mitogen-associated protein kinase (MAPK) that, in turn, phosphorylated and activated MAPK-activated protein kinase-2 (MAPKAPK2), Akt2, and ezrin (39, 79, 104) . This pathway is also directly linked to tight junction regulation, as specific NHE3 inhibition reduced paracellular permeability of SGLT1-expressing Caco-2 BBe monolayers during active Na ϩ -glucose cotransport but not when SGLT1 was inhibited by phlorizin (88) .
At a superficial level, one might puzzle at the benefit of Na ϩ -glucose cotransport increasing NHE3-mediated Na ϩ absorption. The most likely explanation is that, in addition to acting as a transporter, SGLT1 serves as a nutrient sensor that activates villus enterocyte absorptive processes more globally (Fig. 3 , A-C). This may have significant benefits under conditions of stress. For example, SGLT1-mediated transport of a nonmetabolizable glu-cose analog reverses cholera toxin-induced NHE3 inhibition (52) . It is therefore likely that tight junction regulation and restoration of NHE3 activity synergize to account for some of the benefit afforded by oral rehydration therapy.
Paracellular Transport: From Physiology to Pathophysiology
Researchers' understanding of physiologic changes in tight junctions prompted them to examine the tight junction in pathologic barrier dysfunction. Tumor necrosis factor-␣ (TNF) had been identified as an autocrine and paracrine regulator of intestinal epithelial tight junction permeability in vitro (86) . Shortly thereafter, it was reported that TNF-neutralizing antibodies were remarkably effective as Crohn's disease treatment (4, 18) and also restored intestinal barrier function in Crohn's disease patients (85) . This placed TNF at center stage in Crohn's disease pathogenesis and prompted investigation of the mechanisms of TNF-induced barrier loss. TNF treatment of Caco-2 BBe monolayers resulted in doubling of MLC phosphorylation (105) . While the increase in MLC phosphorylation and associated loss of barrier function developed over days, acute MLCK inhibition with the specific peptide PIK triggered complete recovery of barrier function and nearly complete normalization of MLC phosphorylation in less than 1 h (105). Thus, TNF uses, in part, a physiological mechanism of tight junction regulation. However, there are also significant differences between Na ϩ -glucose cotransport-induced and TNF-induced barrier loss. While the former is size-selective and not associated with morphologically evident redistribution of tight junction proteins, TNF-induced barrier loss is characterized by tight junction protein endocytosis and relatively non-size-selective increases in paracellular perme-ability (102) . Thus, while MLCK is required for TNF-induced barrier loss and is sufficient to increase paracellular permeability in vitro and in vivo, even absent of other stimuli (77, 84) , other signaling events must also contribute to the impact of TNF on intestinal transport.
To better understand the in vivo contributions of tight junction regulation to immune-mediated diarrhea, a relevant model was required. Disseminated T cell activation following injection of an anti-CD3 antibody induces acute, T-cell-mediated diarrhea in mice and humans (13, 22, 23) that is abrogated by corticosteroids or TNF neutralization (22, 23, 65) . In this model, serum TNF levels peak by 1.5 h and return to baseline within 4 h of anti-CD3 treatment (23) , which closely matched the kinetics of diarrhea development and resolution (65) . Notably, histologic changes in the first 4 h after T cell activation are limited (16) ; severe changes develop only 20 h or more after anti-CD3 treatment (23, 68) . Nevertheless, electron microscopic examination demonstrated that, within 3 h, anti-CD3 treatment induced perijunctional actomyosin contraction that was nearly identical to that previously associated with Na ϩglucose cotransport (3, 16) . Further, anti-CD3 treatment was associated with increased intestinal epithelial MLC phosphorylation within the perijunctional actomyosin ring. In vivo analyses of transmucosal transport showed that anti-CD3 treatment increased albumin leak from the bloodstream into the intestinal lumen, indicative of barrier loss, as well as net fluid secretion, i.e., diarrhea (16) . Both barrier loss and diarrhea were dose-dependently inhibited by luminal administration of the specific MLCK inhibitor PIK (16) . Further, mice lacking the intestinal epithelial MLCK isoform long MLCK were protected from anti-CD3-induced barrier loss and diarrhea. Fig. 3 . States of malabsorption and diarrhea in the small intestine. A: under normal conditions, transcellular Na ϩ absorption occurs primarily via NHE3 and water is absorbed paracellularly. B: SGLT1 serves as a nutrient sensor and triggers rearrangement of the tight junction to increase paracellular fluid and nutrient absorption. C: SGLT1 also increases NHE3 activity that mediates greater Na ϩ absorption and further increases the osmotic gradient for water absorption across the tight junction. D: pathologic barrier dysfunction, i.e., paracellular permeability increases, can enhance fluid absorption when the transepithelial osmotic gradient is maintained. This occurs experimentally when mice are treated with LIGHT (lymphotoxinlike inducible protein that competes with glycoprotein D for herpesvirus entry mediator on T cells) (17) . E: inhibition of Na ϩ malabsorption leads to a diminished osmotic gradient and less water absorption, ultimately causing mild diarrhea. This occurs experimentally in NHE3 knockout mice (74) . F: in cases where there is both a barrier defect and reduced Na ϩ malabsorption, as in mice treated with TNF (16, 17) , luminal Na ϩ is retained and the osmotic gradient favors movement of fluid from the tissue into the lumen. The barrier dysfunction allows greater fluid efflux than would occur with Na ϩ malabsorption alone.
These data firmly established epithelial MLCK as a critical mediator of physiological and pathophysiological regulation of intestinal epithelial barrier function.
Integration of Paracellular and Transcellular Transport: Back to the Chambers
PIK was able to completely normalize barrier function following anti-CD3 treatment. However, despite inducing a return to net fluid absorption, PIK did not fully restore absorption in quantitative terms (17) . To understand this discordance between fluid transport and barrier function, the effects of individual cytokines elevated following anti-CD3 treatment were assessed. Although serum interferon-␥ (IFN-␥) increased more than 20-fold by anti-CD3 treatment, administration of recombinant IFN-␥ did not acutely affect barrier function or fluid transport. In contrast, administration of either TNF or the TNF-related molecule lymphotoxin-like inducible protein that competes with glycoprotein D for herpesvirus entry mediator on T cells (LIGHT) significantly increased paracellular albumin flux. Notably, unlike the in vitro studies where IFN-␥dependent TNF receptor 2 (TNFR2) expression was required for TNF effects on barrier function, exogenous IFN-␥ was not required for TNF-induced barrier loss.
While the effects of TNF and LIGHT on barrier function and MLC phosphorylation were quantitatively similar, each resulted in only ϳ50% of the barrier loss induced by anti-CD3 treatment (17) . The barrier loss induced by TNF and LIGHT was additive, and combined treatment resulted in paracellular albumin flux that was quantitatively similar to that following anti-CD3 treatment. TNF alone was sufficient to cause net fluid secretion that was quantitatively indistinguishable from that induced by anti-CD3 treatment. In contrast, LIGHT caused a small, but significant increase in fluid absorption (Fig. 3D) . When TNF and LIGHT were combined, the TNF effect dominated, and net fluid secretion was identical to that induced by TNF alone or anti-CD3 (17) .
To explain the discordance between barrier function and fluid flux following TNF or LIGHT treatment, the underlying mechanisms of fluid secretion were considered. Previous analyses showed that neither the cystic fibrosis transmembrane rectifier (CFTR), the dominant chloride channel responsible for fluid secretion in cholera, nor calcium-activated chloride channels were involved in anti-CD3-induced barrier loss or fluid secretion (16) . Conversely, while inhibition of Na ϩ /H ϩ exchangers, including NHE3, either pharmacologically or by elimination of luminal Na ϩ , did not affect anti-CD3-induced barrier loss or fluid secretion, these treatments did reduce the magnitude of net fluid absorption in the absence of T cell activation (16) . Further, pharmacological or genetic NHE3 inhibition or elimination of luminal Na ϩ completely abolished fluid absorption in LIGHT-treated mice (17) . These data suggested that inhibition of Na ϩ /H ϩ exchange might contribute to TNF-induced fluid secretion. That hypothesis was explored in Ussing chambers using Na 22 as a tracer of Na ϩ transport, much as Ussing himself had done half a century earlier. Na ϩ absorption was similar in jejunal mucosae from control or LIGHTtreated mice and was reduced by ϳ80% following treatment with a specific NHE3 inhibitor or in mucosae from NHE3deficient mice (Fig. 3E) . Net Na ϩ absorption in jejunal mucosae from TNF-treated mice was reduced by ϳ80% relative to mucosae from control or LIGHT-treated mice and was not significantly affected by the NHE3 inhibitor (17) . Thus, in addition to triggering MLCK-dependent barrier loss, TNF inhibited NHE3 function.
TNF-induced NHE3 inhibition was associated with movement of NHE3 from the apical brush border into a subapical cytoplasmic compartment. Such NHE3 inhibition had been previously reported following PKC␣ activation. Consistent with PKC␣-mediated NHE3 endocytosis, PKC␣ inhibition prevented both NHE3 removal from the apical membrane and reduced Na ϩ absorption following TNF treatment (17) . Finally, either pharmacological or genetic PKC␣ inhibition prevented diarrhea following TNF treatment, while the PKC␣ activator synergized with LIGHT to cause net fluid secretion (17) . Thus, the difference in fluid movement following TNF or LIGHT treatment can be explained by the observations that, while both LIGHT and TNF activate MLCK to effect barrier loss, only TNF triggers PKC␣-dependent NHE3 inhibition (Fig. 3F) . These data reinforce our understanding of the paracellular pathway as a passive transport process driven by electrochemical gradients and demonstrate that NHE3-dependent Na ϩ absorption significantly contributes to the gradients that drive paracellular fluid absorption.
TNF-Induced Tight Junction Reorganization
Despite extensive examination, tight junction protein distribution was only modestly affected by TNF or anti-CD3 treatment (16, 61) . The most notable change was endocytosis of the tight junction protein occludin, which was blocked by either pharmacological or genetic MLCK inhibition (16, 61) . Occludin internalization began in a synchronized fashion 1.5 h after TNF administration and preceded luminal fluid accumulation by 0.75 h (61). Morphometric analysis of electron micrographs demonstrated the appearance of new vesicles with diameters of ϳ80 nm that coincided with occludin internalization. These matured progressively into larger vesicles with diameters of ϳ125 nm, ϳ170 nm, and ϳ240 nm over the next 0.5 h. Correlative immunofluorescent analyses showed the occludincontaining vesicles that appeared at 1.5 h were positive for caveolin-1 and became progressively positive for the early endosomal marker EEA1 over the next 0.5 h. In contrast, clathrin heavy chain did not colocalize significantly with occludin at any time before or after TNF treatment. In vitro studies showed similar internalization of occludin into EEA1positive vesicles after IFN-␥ treatment of T84 intestinal epithelial monolayers (11) or latrunculin-A-mediated actin depolymerization in MDCK cell monolayers (78) . In vivo, pharmacological inhibition of caveolar, but not clathrin-mediated endocytosis or micropinocytosis, prevented TNF-induced occludin endocytosis, barrier loss, and net fluid secretion (61) . This correlated with in vitro studies of IFN-␥-and TNFinduced occludin internalization in Caco-2 monolayers as well as latrunculin-A-induced occludin internalization in MDCK monolayers, but were not consistent with studies concluding that macropinocytosis was responsible for occludin endocytosis in IFN-␥-treated T84 cells (11) . The difference may well reflect nonspecific effects of pharmacological inhibitors under the conditions of those studies. The ultimate evidence is that caveolin-1 knockout prevented in vivo TNF-induced occludin endocytosis, barrier loss, and net fluid secretion (61) . Consistent with this, expression of dominant negative dynamin, which blocks clathrinand caveolin-1-mediated endocytosis, but not micropinocytosis, prevented latrunculin-A-induced occludin internalization in MDCK monolayers (78) . Internalization of occludin and other proteins via clathrin-mediated endocytosis has also been reported. This is unlikely to be physiologically relevant, as the conclusion is largely based on studies using pharmacological inhibitors and has not been replicated in vivo (40) . Nevertheless, these studies do underscore the importance of occludin, which is further emphasized by in vivo the observation that occludin overexpression limits TNF-induced barrier loss and diarrhea as well as reports that occludin knockdown reduces barrier function in cultured intestinal epithelial cells and mouse intestine (1, 12) . While not proven, it is likely that occludin is degraded following internalization, thereby explaining the reduction in occludin expression that is seen in chronic disease (37) .
The data above and other work link MLCK-dependent, caveolin-1-mediated occludin endocytosis to TNF-and LIGHT-induced, MLCK-dependent barrier loss (60, 61, 75) . This, however, seemed at odds with reports that intestinal barrier function was unaffected by occludin knockout (73) . Nevertheless, intestinal epithelial overexpression of occludin partially protected against TNF-induced barrier loss and restored net fluid absorption (61) . Potential explanations to resolve the paradox presented by these conflicting results include the possibility that knockout mice are able to compensate for intestinal epithelial occludin loss, perhaps by upregulating another tight junction-associated MARVEL protein (TAMP) (69), or, alternatively, that the contributions of occludin to tight regulation are more important than those to basal barrier function. Studies of the responses of occludin-deficient mice to stress, which have not been reported to date, may provide better understanding. Nevertheless, the in vitro observations that barrier function is reduced in a manner similar to that induced by TNF in occludin-deficient Caco-2 BBe monolayers (12) , that TNF does not cause further barrier loss in either Caco-2 BBe or MDCKII monolayers lacking occludin (12, 97) , and that disruption of occludin-ZO-1 binding prevents both TNF-induced barrier loss and occludin endocytosis (12) provide strong evidence that occludin is a critical component of the circuitry responsible for TNF-induced barrier loss and diarrhea.
Towards an Understanding of Barrier Loss in Chronic Disease
Barrier loss alone does not trigger human or experimental inflammatory bowel disease in otherwise normal subjects, as demonstrated by the observation that neither mice nor humans with chronically increased intestinal permeability develop disease (38, 63, 84) . However, epithelial injury can contribute to a susceptible host developing inflammatory bowel disease, as demonstrated by acceleration of disease pathogenesis by either NSAIDs or H. hepaticus infection in IL-10 knockout mice (35, 62) and, potentially, the small increases in inflammatory bowel disease incidence following an episode of infectious gastroenteritis (33) . To better define the contributions of isolated tight junction barrier loss to chronic colitis, transgenic mice expressing a constitutively active myosin light chain kinase (CA-MLCK) within the intestinal epithelium were developed (84) . Despite increased paracellular permeability, these mice are clinically normal (84) , much like some fist degree relatives of Crohn's disease patients (38) . Thus, the CA-MLCK transgenic mice may be a model of healthy subjects who are at risk of developing inflammatory bowel disease. Consistent with this, CA-MLCK transgenic mice display subclinical mucosal immune activation characterized by TH1 immune polarization. Nevertheless, CA-MLCK transgenic mice develop disease more rapidly and suffer greater morbidity and mortality when studied in the context of chronic, immune-mediated, adoptive transfer colitis (84) . Thus, while tight junction barrier loss is insufficient to cause disease in an immunologically intact individual, it can accelerate development and augment disease progression (84) . Further, these data demonstrate that MLCKdependent barrier regulation, which is both physiologically and pathophysiologically relevant, is sufficient to promote disease.
While increased MLCK activity can enhance disease, whether MLCK inhibition can prevent or limit disease remained unknown. The question is relevant, however, as MLCK expression is transcriptionally upregulated by TNF in experimental models (34, 102) and in patients with active inflammatory bowel disease (9) . This was initially explored by taking advantage of the observation that intestinal epithelial TNFR2 expression is required for activation of MLCK (103) . By using the adoptive transfer colitis model, it was possible to provide lymphocytes with normal TNFR1 and TNFR2 expression to recipient mice lacking TNFR1 or TNFR2 on other cell types (83) . TNFR2, but not TNFR1, knockout recipients were markedly protected from disease in terms of weight loss, mucosal TNF production, and histopathology (Fig. 4 ). This could be explained by the absence of increased intestinal epithelial MLCK expression and MLC phosphorylation in TNFR2, but not TNFR1, knockout recipients (83) . Further study using wild-type donor lymphocytes and recipient mice lacking the epithelial long MLCK isoform showed decreased MLC phosphorylation and reduced histopathology relative to MLCKexpressing mice (Fig. 4) . The long MLCK knockout mice also displayed preservation of barrier function and body weight, and reduced mucosal TNF production and clinical scores at early, but not late times during disease development (83) . This apparent failure of MLCK knockout to prevent disease was explained by progressively greater immune-mediated epithelial damage as disease advanced. One way to explain these data is that epithelial damage sufficient to cause tight junction independent barrier loss made inhibition of MLCK-dependent barrier loss irrelevant late in the disease course. Consistent with this, MLCK knockout mice were protected from epithelial apoptosis at early, but not late stages of disease (83) . This protection was not a direct effect of MLCK deficiency, as acute, high-dose TNF administration caused similar degrees of epithelial apoptosis in wild-type and long MLCK knockout mice. Further, when subjected to the epithelial injury-dependent DSS model of colitis, disease was actually more severe in long MLCK knockout, relative to wild-type, mice. Thus, while epithelial MLCK inhibition has promise in immune-mediated diseases, such as inflammatory bowel disease, it may actually be harmful in disorders dominated by epithelial injury. This can be understood when one recalls that MLCK is important to both epithelial migration and wound closure (72) .
Future Opportunities
Despite these and many other significant advances in our understanding of epithelial transport, much remains to be explored. This is true in terms of fundamental discovery, and particularly pressing if this knowledge is to be used for therapeutic benefit. As one example, although the data above suggest that clinical use of MLCK inhibitors may have promise, the identity of smooth muscle and epithelial MLCK catalytic domains presents a potential obstacle to developing therapies that target MLCK, as smooth muscle MLCK inhibition is likely to result in hypotension, intestinal dysmotility, and dysfunction of other organs, e.g., the bladder (36) . In addition, the complex physiologic interactions between occludin, ZO-1, and the claudin family have yet to be fully elucidated, although these do appear to be critical tight junction regulation. Other gaps in understanding of transcellular transport and its integration with paracellular transport also remain to be filled. Finally, while the gastrointestinal microbiome has become a frequent topic of study, little is known about how interactions with luminal bacteria, viruses, and other materials impact epithelial transport and barrier functions. Nevertheless, epidemiological studies linking acute infectious gastroenteritis to subsequent development of inflammatory bowel disease suggest that this may be a particularly fruitful future avenue for investigation. Thus, much remains to be done. The great strides forward in our understanding of epithelial transport in the relatively short time since Ussing created his chamber are, nevertheless, remarkable. And, as is often the case, this knowledge has led to even more exciting frontiers for exploration.
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